Relmada Therapeutics RLMD
NASDAQ RLMD
$3.30 +0.09 (+2.80%)
As of: Oct 22, 2026 · 10:45 AM EDT

Relmada Therapeutics (RLMD) EBIT Margin (2012 - 2023)

Updated

Relmada Therapeutics' EBIT Margin came in at -877.66% for FY2013, down 725.89 percentage points from -151.77% in FY2012.

Analysis

Relmada Therapeutics (RLMD) EBIT Margin (2012 - 2023) Analysis & Trends

  • Per Business Quant, earlier years put EBIT Margin at -151.77% in FY2012.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Eli Lilly 1,162.99 Bn 1,131.58 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 633.71 Bn 552.23 Bn 17.26 Bn 28.21%
3 AbbVie 502.40 Bn 475.51 Bn 12.70 Bn 37.86%
4 Merck 376.48 Bn 330.86 Bn 12.21 Bn -3.52%
5 Novartis Ag 303.61 Bn 267.60 Bn 11.24 Bn 32.97%
6 Astrazeneca 267.02 Bn 240.70 Bn 12.86 Bn 20.57%
7 Amgen 240.85 Bn 196.25 Bn 7.24 Bn 34.95%
8 Gilead Sciences 193.39 Bn 167.58 Bn 6.22 Bn -133.21%
9 Pfizer 172.14 Bn 118.78 Bn 10.94 Bn 28.37%
10 Relmada Therapeutics 370.84 Mn -187.75 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 -2,130.62%
Sep 30, 2023 -1,717.26%
Jun 30, 2023 -1,908.95%
Mar 31, 2023 -5,204.74%
Dec 31, 2022 -3,579.66%
Sep 30, 2022 -14,564.87%
Jun 30, 2022 -11,051.05%
Mar 31, 2022 -12,160.73%
Dec 31, 2021 -95,047.20%
Dec 31, 2020 -9,329.66%
Sep 30, 2020 -4,729.86%
Sep 30, 2019 -9,777.96%
Mar 31, 2019 -16,952.16%
Sep 30, 2017 -177.52%
Jun 30, 2017 -865,477.67%
Mar 31, 2017 -482,653.70%
Jun 30, 2016 -163,632.54%
Mar 31, 2016 -353,096.14%
Jun 30, 2015 -925,710.10%
Mar 31, 2015 -198,797.52%
API Access

Relmada Therapeutics EBIT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit-margin&ticker=RLMD&period=max&api_key=YOUR_API_KEY